John Stagg

18.9k total citations · 5 hit papers
110 papers, 11.1k citations indexed

About

John Stagg is a scholar working on Oncology, Physiology and Immunology. According to data from OpenAlex, John Stagg has authored 110 papers receiving a total of 11.1k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 56 papers in Physiology and 46 papers in Immunology. Recurrent topics in John Stagg's work include Adenosine and Purinergic Signaling (56 papers), Cancer Immunotherapy and Biomarkers (38 papers) and Peptidase Inhibition and Analysis (25 papers). John Stagg is often cited by papers focused on Adenosine and Purinergic Signaling (56 papers), Cancer Immunotherapy and Biomarkers (38 papers) and Peptidase Inhibition and Analysis (25 papers). John Stagg collaborates with scholars based in Canada, Australia and Belgium. John Stagg's co-authors include Mark J. Smyth, Bertrand Allard, Sandra Pommey, Phillip K. Darcy, Jacques Galipeau, Paul A. Beavis, David Allard, Upulie Divisekera, Sherene Loi and Simon C. Robson and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

John Stagg

108 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

2020 910 citations Lukas F. Mager, Regula Burkhard et al. Science profile →
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

2017 686 citations Bertrand Allard, John Stagg et al. profile →
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

2010 479 citations John Stagg, Upulie Divisekera et al. profile →
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

2013 387 citations Sherene Loi, Sandra Pommey et al. profile →
The adenosine pathway in immuno-oncology

2020 370 citations Bertrand Allard, David Allard et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Stagg Canada	47	5.0k	4.4k	4.1k	3.3k	1.3k	110	11.1k
Silvia Deaglio Italy	56	2.6k 0.5×	4.5k 1.0×	3.7k 0.9×	3.1k 0.9×	2.6k 2.0×	226	11.4k
Paulo C. Rodrı́guez United States	52	5.1k 1.0×	10.6k 2.4×	349 0.1×	3.6k 1.1×	436 0.3×	124	15.2k
Roberto M. Lemoli Italy	48	1.8k 0.4×	3.1k 0.7×	972 0.2×	2.1k 0.6×	896 0.7×	239	7.7k
Alma Zernecke Germany	66	2.7k 0.5×	8.7k 2.0×	348 0.1×	5.6k 1.7×	478 0.4×	173	16.0k
Antoine Tesnière France	20	3.2k 0.6×	4.7k 1.1×	477 0.1×	2.1k 0.6×	151 0.1×	27	7.6k
Bin Zhang United States	46	2.9k 0.6×	2.9k 0.7×	418 0.1×	2.3k 0.7×	135 0.1×	167	6.2k
Nicholas D. Huntington Australia	51	3.0k 0.6×	7.0k 1.6×	252 0.1×	2.5k 0.8×	365 0.3×	111	10.1k
Jörg Wischhusen Germany	41	2.6k 0.5×	2.3k 0.5×	240 0.1×	2.7k 0.8×	1.4k 1.1×	91	6.7k
Greg M. Delgoffe United States	48	4.3k 0.9×	7.7k 1.8×	219 0.1×	3.8k 1.1×	242 0.2×	109	11.9k
Veronika Sexl Austria	51	3.6k 0.7×	4.4k 1.0×	211 0.1×	3.3k 1.0×	1.1k 0.9×	183	9.5k

Countries citing papers authored by John Stagg

Since Specialization

Citations

This map shows the geographic impact of John Stagg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Stagg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Stagg more than expected).

Fields of papers citing papers by John Stagg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Stagg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Stagg. The network helps show where John Stagg may publish in the future.

Co-authorship network of co-authors of John Stagg

This figure shows the co-authorship network connecting the top 25 collaborators of John Stagg. A scholar is included among the top collaborators of John Stagg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Stagg. John Stagg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allard, David, et al.. (2024). Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. Cancer Research. 85(4). 692–703. 7 indexed citations

Desmoulins, Isabelle, Emanuela Romano, Vincent Remouchamps, et al.. (2024). 2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC). Immuno-Oncology Technology. 24. 100886–100886.

Stagg, John, et al.. (2024). Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies. The Annual Review of Pharmacology and Toxicology. 65(1). 315–331. 5 indexed citations

Messaoudi, Nouredin, Rolando Rebolledo, Emmanuel Montagnon, et al.. (2023). Radiomics using computed tomography to predict CD73 expression and prognosis of colorectal cancer liver metastases. Journal of Translational Medicine. 21(1). 507–507. 13 indexed citations

Allard, Bertrand, Célia Jacoberger-Foissac, Isabelle Cousineau, et al.. (2023). Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma. Cell Reports Medicine. 4(9). 101188–101188. 19 indexed citations

Laplante, Patrick, Dominique Trudel, Jean‐Baptiste Lattouf, et al.. (2022). High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer Patients. Cancers. 14(11). 2790–2790. 6 indexed citations

Messaoudi, Nouredin, Isabelle Cousineau, Ève Simoneau, et al.. (2022). Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns. British Journal of Cancer. 126(9). 1329–1338. 10 indexed citations

Kilgour, Marisa K., Sarah MacPherson, Lauren G. Zacharias, et al.. (2021). 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. Science Advances. 7(4). 51 indexed citations

Mager, Lukas F., Regula Burkhard, Nicola Pett, et al.. (2020). Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 369(6510). 1481–1489. 910 indexed citations breakdown →

10.

Allard, David, et al.. (2018). CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination. PLoS ONE. 13(1). e0191973–e0191973. 5 indexed citations

11.

Beavis, Paul A., Melissa A. Henderson, Lauren Giuffrida, et al.. (2017). Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation. 127(3). 929–941. 259 indexed citations

12.

Charlebois, Roxanne, Bertrand Allard, David Allard, et al.. (2016). PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors. Cancer Research. 77(2). 312–319. 26 indexed citations

13.

Mittal, Deepak, Debottam Sinha, Deborah S. Barkauskas, et al.. (2016). Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. Cancer Research. 76(15). 4372–4382. 142 indexed citations

14.

Turcotte, Martin, Kathleen Spring, Sandra Pommey, et al.. (2015). CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancer Research. 75(21). 4494–4503. 207 indexed citations

15.

Beavis, Paul A., Nicole Milenkovski, Melissa A. Henderson, et al.. (2015). Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunology Research. 3(5). 506–517. 270 indexed citations

16.

Charlebois, Roxanne, Guillaume Chouinard, Bertrand Allard, et al.. (2015). CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. Clinical Cancer Research. 22(1). 158–166. 162 indexed citations

17.

Allard, Bertrand, Sandra Pommey, Mark J. Smyth, & John Stagg. (2013). Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. Clinical Cancer Research. 19(20). 5626–5635. 372 indexed citations

18.

Stagg, John, Paul A. Beavis, Upulie Divisekera, et al.. (2012). CD73-Deficient Mice Are Resistant to Carcinogenesis. Cancer Research. 72(9). 2190–2196. 174 indexed citations

19.

Stagg, John, Upulie Divisekera, Helene Duret, et al.. (2011). CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis. Cancer Research. 71(8). 2892–2900. 320 indexed citations

20.

Street, Shayna E.A., Nadeen Zerafa, Manuela Iezzi, et al.. (2007). Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma. Cancer Research. 67(11). 5454–5460. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact